CatalystMarker
← board

DERM

distress 2/10 · well-funded / low risk
$7.01-2%today-24% from 52w high
journeymedicalcorp.com58 employeesFounded 2014Scottsdale, AZDrug Manufacturers - Specialty & Generic
Revenue
$16M
Liquidity
$27M
Runway
4.1 yrs
Shares 1y

Price & events

-24.3% over 6M
$4.39$6.83$9.26Jan 26Apr 26Jul 262.1Mdilution: 424B3 offering (2026-01-23)dilution: 424B3 offering (2026-01-23)rating: HC Wainwright & Co.: Buy (2026-03-26)
CatalystRating changeDilutionFinancingdashed = today
-1.5%
1D
-1.4%
1W
+4.6%
1M
+36.6%
3M
-19.2%
6M
-5.1%
1Y
+29.6%
2Y
5Y
-29.2%
All

Overview

Volume
22.06K
52 Week Range
$4.39 – $9.26
Float Shares
14.90M
Short %
19.73%
% Held by Insiders
32.77%
% Held by Institutions
59.25%
RVOL
0.08x
Beta
1.07

Pipeline · 0 trials · 0 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
No pipeline trials tracked.

Catalyst news & presentations · 3

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: · 3 offerings/1y · 0 PIPEs
  • 2026-01-23424B3offering
  • 2026-01-23424B3offering
  • 2026-01-21EFFECTshelf_effective
  • 2026-01-15S-3shelf_registration
  • 2025-09-268-Kmaterial_agreement
  • 2025-08-288-Kmaterial_agreement
  • 2025-08-28424B3offering
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

strong buy · target $14 (+93% upside) · 4 analysts
  • 2026-03-26HC Wainwright & Co.Buy
  • 2025-08-25HC Wainwright & Co.Buy
  • 2025-08-13Lake StreetBuy
  • 2025-07-30B. Riley SecuritiesBuy

Competitors

  • none identified

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.